ライフサイエンスコーパス: biotech

1 Robert Wood Johnson Foundation, and Janssen Biotech.

2 h Care, Chugai, Pharmion, Celgene, and Ortho Biotech.

3 randomisation scheme was generated by Facet Biotech.

4 h Care, Chugai, Pharmion, Celgene, and Ortho Biotech.

5 ent will KSR limit combination inventions in biotech?

6 Carlsbad, CA) and BeeBlot/ViraScan (Viramed Biotech AG, Munich, Germany), using 518 serum specimens

7 iotech], and Treponema ViraBlot IgG [Viramed Biotech AG, Planegg, Germany]) using serum samples (n =

8 r therapeutics, why academic researchers and biotech and pharmaceutical companies are so excited, and

9 ic exploration of methods for distinguishing biotech and pharmaceutical companies yields a dynamic, m

10 TP) rights in agricultural biotechnology (ag-biotech) and transgenic plants has become critically imp

11 tory agency representatives; pharmaceutical, biotech, and food industry leaders; patent attorneys; ec

12 EIA [Phoenix Biotech], Trep-ID EIA [Phoenix Biotech], and Treponema ViraBlot IgG [Viramed Biotech AG

13 as a potential surrogate for PHHs in various biotech applications.

14 ld the potential for both basic research and biotech applications.

15 There is an increasing demand for biotech-based production of recombinant proteins for use

16 ked to treatment with the exception of Facet Biotech bioanalysts who prepared data for the data safet

17 res, especially in the context of a maturing biotech business 'ecosystem'.

18 the multicenter trial of SYNSORB Pk (SYNSORB Biotech, Calgary, Alberta, Canada) treatment for D+HUS.

19 tested with the Abbott Determine and Trinity Biotech Capillus SR tests in parallel.

20 erpretive systems, TrinBlot/BLOTrix (Trinity Biotech, Carlsbad, CA) and BeeBlot/ViraScan (Viramed Bio

21 tibody assay (DFA) for RSV (Bartels; Trinity Biotech, Carlsbad, CA), and two DFAs for hMPV manufactur

22 tlier companies, and confirm that nearly all biotech companies are loss-making enterprises, exhibitin

23 In response, a plethora of small biotech companies have emerged with an interest in antib

24 Pharmaceutical and biotech companies have leveraged the incentivized benefi

25 An analysis of 105 mergers among small UK biotech companies over a 10-year period shows that the i

26 tance of patenting by small and medium-sized biotech companies.

27 bodies in clinical trials are owned by small biotech companies.

28 functions can jeopardize the trust between a biotech company and it stakeholders.

29 hnique has been exploited by Cambridge-based biotech company Biotica Technology Ltd, and their collab

30 e (IDRI), which operates as a not-for-profit biotech company, may start to pay off during the H1N1 's

31 (OTC), one from Cambridge Biotech Corp.

32 were manufactured by Alexon, Inc., Cambridge Biotech Corp., Meridian, Inc., and Trend Scientific, Inc

33 e significant contributions to production of biotech crops for food, feed, valuable recombinant prote

34 So this leaves one with the question of 'can biotech deliver the new antibiotics?'.

35 Widespread adaptation of biotech-derived products of agriculture should lay the f

36 A young biotech firm can grow in several ways.

37 e, experts from a large pharma company and a biotech firm provide their perspectives.

38 emia and large pharmaceutical companies, the biotech firms have been effective instruments of technol

39 ttle is known about the multitude of private biotech firms.

40 ott HIV-1) and Western blot assay (Cambridge-Biotech) for HIV-1 antibody.

41 201 (Enzo Life Sciences), and SKR038 (GenWay Biotech Inc San Diego USA) immunoassays, as well as spik

42 ert support with no sugar attached) (Synsorb Biotech Inc.) was measured.

43 o explore the ability of Synsorb 90 (Synsorb Biotech Inc., Calgary, Alberta, Canada), and inert suppo

44 s of escalating doses of Marimastat (British Biotech, Inc, Oxford, United Kingdom) in patients with a

45 at (BB-94 and BB-2516, respectively, British Biotech, Inc.); CT1418 (Celltech Therapeutics); CGS27023

46 clinical trials include SYNSORB Pk (SYNSORB Biotech, Inc., Calgary, Alberta, Canada), a drug designe

47 s treated with infliximab (Remicade; Janssen Biotech, Inc., Titusville, NJ) were identified through a

48 matter of semantics-the core identity of the biotech industry and its products is at stake.

49 impact on crop production, development of a biotech industry and the bio-based economy worldwide.

50 The biotech industry is establishing itself as the discovery

51 ollaborative research may end up costing the biotech industry more and inhibiting innovation.

52 Engineering robust microbes for the biotech industry typically requires high-level, genetica

53 ods for carbohydrate characterization in the biotech industry were compared.

54 enzymes (CAZymes) are very important to the biotech industry, particularly the emerging biofuel indu

55 mbinant protein titer is a major goal of the biotech industry.

56 is one of the greatest challenges facing the biotech industry.

57 It is now a seller's market in the biotech industry.

58 titutes of Health, Bethesda, USA; and Bharat Biotech International, Hyderabad, India.

59 oassay (EIA), the CAPTIA Syphilis-G (Trinity Biotech, Jamestown, N.Y.), has become available as a dia

60 al to investigate the effect of ATLG (Neovii Biotech, Lexington, MA) on cGVHD-free survival.

61 , Trep-Sure enzyme immunoassay [EIA; Phoenix Biotech, Oakville, Ontario, Canada], Trep-Chek EIA [Phoe

62 Many of the antibiotic biotech organizations that were most likely to undertake

63 croalgae, biotech yeast, and, in the future, biotech plant oils).

64 validated the Capillus HIV-1/HIV-2 (Trinity Biotech PLC, Bray, County Wicklow, Ireland) and Determin

65 of using these engineered strains in common biotech processes.

66 ntify these rights, a transgenic plant or ag-biotech product must be dissected into its essential com

67 issues of releasing a transgenic plant or ag-biotech product; rather, it is a management tool for ass

68 Transgenic plants and ag-biotech products embody numerous components and processe

69 production of SLM for biopharmaceutical and biotech protocols.

70 ibine (2-chlorodeoxyadenosine [2-CdA]; Ortho Biotech, Raritan, NJ) is a newer purine analog with pote

71 g increased adoption of (13)C MFA within the biotech research community.

72 The existence of a medicinal 'biotech revolution' has been widely accepted and promote

73 After a decade of significant challenges, biotech's long-term sustainability depends on making fun

74 We find that the performance of the biotech sector is highly sensitive to the presence of a

75 The biotech sector must not only maintain an emphasis on gro

76 China sets its sights on joining the global biotech sector.

77 financial performance of the privately held biotech sector.

78 Few things are misunderstood more by biotech startup management teams than the importance of

79 When transferring transgenic plants or ag-biotech to developing nations, scientists from industria

80 le, Ontario, Canada], Trep-Chek EIA [Phoenix Biotech], Trep-ID EIA [Phoenix Biotech], and Treponema V

81 ser guide are freely available at http://www.biotech.ufl.edu/people/sun/esprit.html.

82 RealArt Parvovirus B19 LC PCR reagent (artus biotech USA, San Francisco, Calif.) for real-time PCR de

83 ion information are available at http://gaia.biotech.vt.edu/goat.

84 mercial License are available at http://gaia.biotech.vt.edu/goat/.

85 obesity drugs, a chemical library from Vivia Biotech was screened using ExviTech platform.

86 investment that aligns plant and industrial biotech will pay dividends for sustainable energy and ma

87 ation about the publicly traded elite of the biotech world, little is known about the multitude of pr

88 derived from nonanimal sources (microalgae, biotech yeast, and, in the future, biotech plant oils).